



Supplementary Table 1. Hematologic and non-hematologic side effects in INT-1 and INT-2/high-risk patients.

Variables, N (%)	INT-1 risk	INT-2/high risk	<i>P</i>
Hematologic	30 (90.9)	22 (91.7)	0.92
Anemia	26 (78.8)	22 (91.7)	0.19
Grade 1-2	16 (48.5)	8 (33.3)	
Trombocytopenia	14 (42.4)	8 (33.3)	0.49
Grade 1-2	7 (21.2)	5 (7.8)	
Non-hematologic, N (%)	17 (51.5)	10 (41.7)	0.46



Supplementary Fig. 1. Doses, discontinuation rates, and dose interruption status of ruxolitinib during the follow-up.



Supplementary Fig. 2. Hemoglobin and platelets counts during the follow-up.